Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.9252W HIGH $24.59
Volume
119.32 K
Value Traded
3.09 M
Short % Float
6.24%
Days to Cover
6.4
-1.29%Week
+2.03%1 Month
-14.52%3 Month
+46.82%6 Month
-6.41%5 Year
-6.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
398.27 M
EPS (TTM)
-1.68
P/E Ratio
-
Ent. Value
314.09 M
Total Shares
20.83 M
Float Shares
11.38 M
Insiders
45.32%
Institutions
40.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SI Catalyst Timeline
Dated clinical, regulatory and corporate events for Shoulder Innovations, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Shoulder Innovations, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
▲Debt Royalty FinancingCorporate
Closed up to $50 million credit facility with Stifel Venture Banking
Past FDA Catalysts and PDUFA Decisions
How SI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Shoulder Innovations, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ball Robert JosephDirector, Officer (CEO & Executive Chairman) | Option | 89,233 390,999 held | $2.10 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.5 % | 4.59 M | 226.21 K |
SI Institutional Ownership Trends
SI Short Interest
Shares sold short, counted twice a month.
6.24%
Short % of Float
of tradable shares sold short
710.1K
Shares Sold Short
+12.7% vs prior count
6.4 High
Days to Cover
trading days of normal volume to buy every short share back
111.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SI ranks across every disease it competes in
Competitive Position is a premium feature
See how SI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSI News
SI▼ -4.6%today
Shoulder Innovations to Participate in Upcoming Investor Conferences
Shoulder Innovations announced management participation in two investor conferences. The company will present at the UBS Global Healthcare Conference on November 10. It will also speak at the Jefferies Global Healthcare Conference on November 17. Both events will feature webcasts for investors.
Read more →SIShoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026
Shoulder Innovations, Inc. will announce its third quarter 2026 financial results on November 5, 2026, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results. The company aims to improve shoulder surgical care through advanced implant systems and an ecosystem designed for efficiency and better outcomes.
Read more →SIShoulder Innovations Initiates Commercial Launch of the InSet® Go
Shoulder Innovations has launched a limited user release of the InSet® Go, a next-generation glenoid implant designed for anatomic shoulder arthroplasty. The first surgery using this implant was successfully completed by Dr. Robert Gillespie. This new technology aims to enhance stability and reduce surgical complexity, building on over 20 years of innovation in shoulder surgery.
Read more →SIShoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch
Shoulder Innovations has received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant designed for patients with metal hypersensitivity. This product complements the previously cleared N-22 Glenosphere implant, enhancing options for surgeons in shoulder arthroplasty. The company aims to improve surgical care and outcomes for patients with metal allergies.
Read more →SIShoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures
Shoulder Innovations has partnered with ALM Ortho to create bespoke implants for complex shoulder reconstruction. This collaboration aims to address the lack of adequate solutions for severe shoulder deformities. Shoulder Innovations will utilize its existing relationships to connect surgeons with ALM Ortho's personalized implant solutions. The partnership is expected to enhance patient outcomes and strengthen Shoulder Innovations' market position.
Read more →SIShoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience
Shoulder Innovations has announced a settlement with Catalyst OrthoScience to resolve all patent litigation. The terms of the agreement remain confidential. CEO Rob Ball expressed satisfaction with the resolution, emphasizing the importance of protecting intellectual property to benefit stakeholders. This settlement allows the company to continue advancing shoulder surgical care.
Read more →SIShoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference
Shoulder Innovations, Inc. will participate in the Morgan Stanley 24th Annual Healthcare Conference on September 15, 2026. The management team will engage in a fireside chat at 3:20 p.m. ET. The event will be accessible via a live and archived webcast on the company's website, enhancing investor engagement.
Read more →SIShoulder Innovations Promotes Jon Osborne to Chief Commercial Officer
Shoulder Innovations has promoted Jon Osborne to Chief Commercial Officer, effective August 6, 2026. Osborne, previously the Vice President of Commercial Development, will oversee the company's commercial organization and enhance relationships with surgeons. His extensive experience in the orthopedic industry is expected to drive further growth and adoption of Shoulder Innovations' product portfolio.
Read more →SI▼ -8.2%on this newsshared move
Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook
Shoulder Innovations reported a strong second quarter for 2026, achieving a 56% increase in net revenue, totaling $17.2 million. The company also raised its full-year revenue guidance to between $67 million and $69 million, reflecting a growth of 42% to 46% over the previous year. Despite the positive revenue growth, the company experienced an increase in operating loss and administrative expenses.
Read more →SIShoulder Innovations to Participate in the Canaccord Genuity 46th Annual Growth Conference
Shoulder Innovations, Inc. will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company specializes in shoulder surgical care and offers advanced implant systems for shoulder arthroplasty. A live webcast of the presentation will be available on their website.
Read more →SIShoulder Innovations to Report Second Quarter 2026 Financial Results on August 6, 2026
Shoulder Innovations, Inc. will report its financial results for Q2 2026 on August 6, 2026. The company, focused on shoulder surgical care, will host a conference call at 4:30 p.m. ET to discuss these results. Interested parties can access the call via phone or through a webcast on their website.
Read more →SI▼ -7.5%on this news
Shoulder Innovations Announces Closing of up to $50 Million Credit Facility
Shoulder Innovations has successfully closed two credit facilities totaling up to $50 million with Stifel Venture Banking. This includes a $15 million term loan to refinance existing debt and a $30 million line of credit. The new terms significantly improve the company's financial structure and provide additional working capital to support its growth in the shoulder surgical care market.
Read more →SIShoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Shoulder Innovations, Inc. has announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 9, 2026. The company is focused on transforming the shoulder surgical care market with advanced implant systems. Their ecosystem aims to enhance preoperative planning and procedural efficiency, addressing challenges in shoulder surgical care.
Read more →SIShoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
Shoulder Innovations reported a strong financial performance for Q1 2026, with net revenue increasing by 65% to $16.7 million compared to the previous year. The company also raised its full year revenue guidance to between $65 million and $68 million, indicating robust growth prospects. However, the company faced increased operating losses and higher expenses in both selling and R&D.
Read more →SIShoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem
Shoulder Innovations has officially launched the InSet I-135RFX Humeral Stem after a successful limited market release and FDA clearance for additional fracture indications. This product expands their offerings in shoulder arthroplasty, allowing use in all primary, revision, and fracture procedures. The launch signifies a milestone for the company and showcases their dedication to improving surgical care.
Read more →SIShoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026
Shoulder Innovations, Inc. will announce its financial results for Q1 2026 on May 13, 2026. The company is focused on improving shoulder surgical care and will host a conference call to discuss the results. Interested parties can access the call through provided contact details.
Read more →SIShoulder Innovations Reports Fourth Quarter and Full Year 2025 Financial Results
Shoulder Innovations, Inc. (NYSE: SI) reported strong financial results for the fourth quarter and full year of 2025, with fourth-quarter net revenue soaring 65% year-over-year to $14.4 million. The company also experienced a 50% increase in full-year revenue, reaching $47.3 million. Looking ahead, management projects a net revenue forecast of $62 million to $65 million for 2026, indicating continued growth. However, the company recorded a higher operating loss and net loss in Q4 2025 compared to the previous year, primarily due to increased expenses related to operations and public company costs.
Read more →SIShoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors
Shoulder Innovations has appointed Drew Hykes to its Board of Directors, effective February 26, 2026. Hykes, a seasoned medical device executive, is expected to leverage his extensive experience to support the company's growth in the shoulder surgical care market. His appointment follows Geoff Pardo's resignation from the Board, who expressed confidence in the company's future.
Read more →SIShoulder Innovations to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
Shoulder Innovations, Inc. will present at the Canaccord Genuity 2026 Musculoskeletal Conference on March 3, 2026. The company specializes in advanced implant systems for shoulder surgeries and aims to improve surgical care through innovative technologies. A live stream of the presentation will be available on their website.
Read more →SI▲ +11.2%on this newsshared move
Shoulder Innovations to Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Shoulder Innovations, Inc. will announce its financial results for Q4 and the full year of 2025 on March 10, 2026. The company aims to enhance shoulder surgical care through advanced implant systems and a comprehensive ecosystem. A conference call will follow the results announcement for further discussion.
Read more →About Shoulder Innovations, Inc.
Headquarters1535 STEELE AVENUE SW, SUITE B, GRAND RAPIDS, MI, 49507
BIOPHARMAWATCH ELITE PLUS
Trade the next SI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime